Literature DB >> 35029659

COVID-19 Therapeutics for Nonhospitalized Patients.

Rajesh T Gandhi1, Preeti N Malani2,3, Carlos Del Rio4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35029659     DOI: 10.1001/jama.2022.0335

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Authors:  Yuan-Pin Hung; Jen-Chieh Lee; Chun-Wei Chiu; Ching-Chi Lee; Pei-Jane Tsai; I-Lin Hsu; Wen-Chien Ko
Journal:  Antibiotics (Basel)       Date:  2022-02-09

2.  Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.

Authors:  Andreas Heyer; Thomas Günther; Alexis Robitaille; Marc Lütgehetmann; Marylyn M Addo; Dominik Jarczak; Stefan Kluge; Martin Aepfelbacher; Julian Schulze Zur Wiesch; Nicole Fischer; Adam Grundhoff
Journal:  Cell Rep Med       Date:  2022-08-16

3.  Utilizing labour and delivery units for remdesivir infusion for high-risk pregnant and postpartum patients with mild-to-moderate disease during a COVID-19 surge.

Authors:  R Herz-Roiphe; A Y Kim; A J Kaimal; I T Goldfarb
Journal:  J Hosp Infect       Date:  2022-08-06       Impact factor: 8.944

4.  Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department.

Authors:  Rahul V Nene; Michael R Navarro; Christian A Tomaszewski; Andrew Lafree
Journal:  Ann Emerg Med       Date:  2022-10       Impact factor: 6.762

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.